Related Experiment Video
Updated: Dec 6, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
619
Advancing combination therapy for Alzheimer's disease
Stephen P Salloway1, Jeff Sevingy2, Kumar Budur3
1Brown University Providence Rhode Island USA.
Alzheimer'S & Dementia (New York, N. Y.)
|October 12, 2020
Summary
Combination therapy for Alzheimer's disease (AD) shows promise but faces challenges in preclinical models, clinical trials, and regulations. Experts convened to discuss strategies for developing effective combination treatments for AD.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Research
Background:
- Alzheimer's disease (AD) research has revealed complex pathologies and pathways.
- A combination therapy approach is proposed for more effective AD treatment across various stages.
- Developing combination therapies for AD presents significant challenges.
Purpose of the Study:
- To discuss the approaches and challenges of combination therapy for Alzheimer's disease.
- To gather expert perspectives from academia, industry, and government.
- To identify a path forward for developing novel combination therapies for AD.
Main Methods:
- A Research Roundtable meeting was convened by the Alzheimer's Association.
- Experts from academia, industry, and government participated in the discussion.
- Perspectives on combination therapy development for AD were shared.
Main Results:
- Key challenges in combination therapy development were identified, including limitations of non-clinical models.
- Complexities in clinical trial design for combination therapies were discussed.
- Unclear regulatory requirements for combination treatments were highlighted.
Conclusions:
- Developing effective combination therapies for Alzheimer's disease requires addressing multiple challenges.
- Expert consensus and collaboration are crucial for advancing combination therapy development.
- Establishing clear regulatory pathways and robust preclinical/clinical models is essential for future progress.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
630
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
630
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:24Parkinson's Disease: Treatment
802
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
802
01:26Atherosclerosis III: Management
219
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
219
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
01:28Drug Therapy
184
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
184